Myocardial Infarction

55
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
10
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
11
3
15
24
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
675%
Small Molecule
225%
+ 64 programs with unclassified modality

On Market (10)

Approved therapies currently available

Medicure
AGGRASTATApproved
tirofiban
Medicure
injection1998
U
EMPAGLIFLOZINApproved
empagliflozin
Unknown Company
Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
Bayer
MAGNEVISTApproved
gadopentetate dimeglumine
Bayer
injection1988
Regeneron
PRALUENTApproved
alirocumab
Regeneron
PCSK9 Inhibitor [EPC]injection2015
U
PRASUGRELApproved
prasugrel
Unknown Company
oral2017
U
PRASUGREL HYDROCHLORIDEApproved
prasugrel
Unknown Company
oral2023
U
REOPROApproved
abciximab
Unknown Company
injection1994
U
TIROFIBAN HYDROCHLORIDEApproved
tirofiban
Unknown Company
intravenous2023
Roche
TNKASEApproved
tenecteplase
Roche
2000

Competitive Landscape

34 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
14 programs
1
6
2
TenecteplasePhase 41 trial
TenecteplasePhase 41 trial
EmpagliflozinPhase 3Small Molecule1 trial
Full dose TNK-tPAPhase 31 trial
Full dose tenecteplasePhase 31 trial
+9 more programs
Active Trials
NCT02235389Terminated59
NCT02191670Completed60
NCT02206646Completed987
+11 more trials
Roche
3 programs
1
1
TNKASE(tenecteplase)Phase 2/31 trial
Routine Early Percutaneous Coronary Intervention after ThrombolysisN/A1 trial
Spectral T Wave AlternansN/A1 trial
Active Trials
NCT00164190Completed1,200Est. Jan 2009
NCT00399503Completed350Est. Dec 2007
NCT00121446Completed300
C
CordisFL - Miami Lakes
3 programs
3
AbciximabPhase 4Monoclonal Antibody1 trial
AbciximabPhase 4Monoclonal Antibody1 trial
Endeavor, MedtronicPhase 41 trial
Active Trials
NCT00440778Completed105Est. Oct 2008
NCT00440895Completed74Est. May 2013
NCT00422565Terminated328Est. Sep 2008
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
1
Danhong InjectionPhase 41 trial
Heart rate variability measurementN/A1 trial
Active Trials
NCT05098977UnknownEst. Oct 2024
NCT02158559Unknown
Medicure
2 programs
1
1
1
TirofibanPhase 31 trial
Short TirofibanPhase 21 trial
Active Trials
NCT01522417CompletedEst. Mar 2019
NCT01245725Withdrawn
Sanofi
SanofiPARIS, France
2 programs
1
1
Percutaneous coronary interventionPhase 4
tenecteplasePhase 2/3
Regeneron
RegeneronTARRYTOWN, NY
2 programs
2
AlirocumabPhase 4Monoclonal Antibody1 trial
alirocumabPhase 4Monoclonal Antibody
Active Trials
NCT03750760Withdrawn0Est. Dec 2021
Bayer
BayerLEVERKUSEN, Germany
1 program
1
1
MAGNEVIST(Magnevist)Phase 24 trials
Active Trials
NCT00395733Completed83Est. Oct 2007
NCT00395460Completed147Est. Apr 2007
NCT00310544Completed73Est. Sep 2006
+1 more trials
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
1
CYP2C19 genotypingPhase 41 trial
Active Trials
NCT01761786CompletedEst. Apr 2019
Pfizer
PfizerNEW YORK, NY
1 program
1
Percutaneous coronary interventionPhase 41 trial
Active Trials
NCT00138034Completed49Est. Feb 2010
M&
Merck & Co.RAHWAY, NJ
1 program
1
PrasugrelPhase 41 trial
Active Trials
NCT02545933Completed130Est. Jan 2020
Lantheus Medical Imaging
1 program
1
Technetium Tc99m SestamibiPhase 41 trial
Active Trials
NCT00162331CompletedEst. Jul 2007
Genentech
1 program
1
TenecteplasePhase 4
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
5 programs
2
MD-endorsed Cardiac Rehabilitation referralPhase 31 trial
Ticagrelor 90 mgPhase 31 trial
Mobile-phone based patient supportN/A1 trial
Pattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MIN/A1 trial
Statins and Risk of Myocardial Infarction in Real Life in FranceN/A1 trial
Active Trials
NCT01874262Completed174Est. Dec 2014
NCT03099395Unknown100,000Est. Oct 2017
NCT00679575Completed13,171Est. Nov 2010
+2 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
5 programs
1
3
AbciximabPhase 3Monoclonal Antibody1 trial
Coronary AngioplastyPhase 3
fibrinolytic therapy or combination reduced fibrinolytic therapyPhase 31 trial
tenecteplasePhase 2/3
coronary balloon-angioplasty with stentingN/A
Active Trials
NCT00638638Unknown292Est. Jan 2010
NCT00245648CompletedEst. Oct 2007
Biotronik
BiotronikGermany - Berlin
3 programs
1
Coronary AngioplastyPhase 31 trial
BioMonitorN/A1 trial
Implantable Cardio DefibrillatorN/A1 trial
Active Trials
NCT02341534Completed802Est. Nov 2021
NCT01422174Withdrawn0Est. Jan 2015
NCT00220571Completed600Est. Mar 2007
DS
Daiichi SankyoChina - Shanghai
1 program
1
PrasugrelPhase 31 trial
Active Trials
NCT01327534Completed63Est. Jul 2013
Novo Nordisk
1 program
1
ZiltivekimabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT07301034Recruiting332Est. Feb 2029
Rhythm Pharmaceuticals
4 programs
1
PCIPhase 21 trial
Medtronic Reveal LINQ implantable cardiac monitorN/A1 trial
T Wave Alternans TestN/A1 trial
T Wave Alternans TestN/A1 trial
Active Trials
NCT02594488CompletedEst. Feb 2021
NCT00305240Completed656Est. Feb 2007
NCT00305214Completed405Est. Feb 2007
+1 more trials
Bristol Myers Squibb
3 programs
2
ClopidogrelPhase 2
KAI-9803Phase 21 trial
coronary balloon-angioplasty with stentingN/A
Active Trials
NCT00785954Completed1,180Est. May 2011
Egetis Therapeutics
Egetis TherapeuticsSweden - Stockholm
1 program
1
MangafodipirPhase 21 trial
Active Trials
NCT00966563CompletedEst. Jul 2013
Valo Therapeutics
1 program
1
OPL-0301 Dose 1Phase 21 trial
Active Trials
NCT05327855WithdrawnEst. Nov 2024
Miracor Medical
Miracor MedicalBelgium - Awans
1 program
1
PICSOPhase 21 trial
Active Trials
NCT04032925TerminatedEst. Dec 2022
Genomics
GenomicsUK - Oxford
1 program
1
RamiprilPhase 2Small Molecule1 trial
Active Trials
NCT03715998Completed295Est. Jul 2021
Eagle Pharmaceuticals
Eagle PharmaceuticalsNJ - Woodcliff Lake
1 program
1
SeeMorePhase 21 trial
Active Trials
NCT00881075CompletedEst. Mar 2012
Capricor Therapeutics
1 program
1
CAP-1002 Allogeneic Cardiosphere-Derived CellsPhase 1/21 trial
Active Trials
NCT01458405Terminated135Est. Feb 2019
Stempeutics Research
Stempeutics ResearchIndia - Bangalore
1 program
1
Stem cellPhase 1/21 trial
Active Trials
NCT00883727CompletedEst. Aug 2012
Zoll
ZollCA - San Jose
2 programs
Cologne Register of Wearable Defibrillator (CRWD)N/A1 trial
wearable defibrillatorN/A1 trial
Active Trials
NCT02073942CompletedEst. Mar 2018
NCT01446965CompletedEst. May 2019
Abbott
AbbottABBOTT PARK, IL
2 programs
FFR-guided revascularisation strategyN/A1 trial
i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT AlinityN/A1 trial
Active Trials
NCT01399736Completed885Est. Oct 2018
NCT05629572Completed3,697Est. Mar 2024
Providence Therapeutics
1 program
Colchicine 0.6 mgN/A1 trial
Active Trials
NCT04139655WithdrawnEst. Oct 2021

+4 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
RegeneronAlirocumab
Boehringer IngelheimTenecteplase
Merck & Co.Prasugrel
T-TherapeuticsDanhong Injection
Vera TherapeuticsCYP2C19 genotyping
CordisAbciximab
CordisAbciximab
CordisEndeavor, Medtronic
PfizerPercutaneous coronary intervention
Lantheus Medical ImagingTechnetium Tc99m Sestamibi
Boehringer IngelheimTenecteplase
Novo NordiskZiltivekimab
Boehringer IngelheimEmpagliflozin
Daiichi SankyoPrasugrel
AstraZenecaTicagrelor 90 mg

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 150,093 patients across 50 trials

NCT03750760RegeneronAlirocumab

Early Alirocumab to Reduce LDL-C in Myocardial Infarction

Start: Jan 2020Est. completion: Dec 20210
Phase 4Withdrawn
NCT02777580Boehringer IngelheimTenecteplase

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Start: Aug 2017Est. completion: Sep 2023609 patients
Phase 4Completed
NCT02545933Merck & Co.Prasugrel

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Start: Feb 2016Est. completion: Jan 2020130 patients
Phase 4Completed
NCT02158559T-TherapeuticsDanhong Injection

the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.

Start: Mar 2014
Phase 4Unknown
NCT01761786Vera TherapeuticsCYP2C19 genotyping

Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)

Start: Jun 2011Est. completion: Apr 2019
Phase 4Completed
NCT00440778CordisAbciximab

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI

Start: Feb 2007Est. completion: Oct 2008105 patients
Phase 4Completed
NCT00440895CordisAbciximab

A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI

Start: Feb 2007Est. completion: May 201374 patients
Phase 4Completed
NCT00422565CordisEndeavor, Medtronic

Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

Start: Oct 2006Est. completion: Sep 2008328 patients
Phase 4Terminated
NCT00138034PfizerPercutaneous coronary intervention

APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3

Start: Jan 2005Est. completion: Feb 201049 patients
Phase 4Completed
NCT00162331Lantheus Medical ImagingTechnetium Tc99m Sestamibi

CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI

Start: Jan 2005Est. completion: Jul 2007
Phase 4Completed
NCT00168792Boehringer IngelheimTenecteplase

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

Start: Nov 20031,671 patients
Phase 4Terminated
NCT01245725MedicureTirofiban

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

Phase 3Withdrawn
NCT07301034Novo NordiskZiltivekimab

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Start: Dec 2025Est. completion: Feb 2029332 patients
Phase 3Recruiting
NCT04509674Boehringer IngelheimEmpagliflozin

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Start: Dec 2020Est. completion: Nov 20236,522 patients
Phase 3Completed
NCT01327534Daiichi SankyoPrasugrel

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

Start: May 2011Est. completion: Jul 201363 patients
Phase 3Completed
NCT01225562AstraZenecaTicagrelor 90 mg

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Start: Oct 2010Est. completion: Dec 201421,379 patients
Phase 3Completed
NCT00623623Boehringer Ingelheimprimary PCI

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Start: Mar 2008Est. completion: Sep 20121,899 patients
Phase 3Completed
NCT00395733BayerMagnevist

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Start: Oct 2006Est. completion: Oct 200783 patients
Phase 3Completed
NCT00395460BayerMagnevist

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Start: Sep 2006Est. completion: Apr 2007147 patients
Phase 3Completed
NCT00638638Eli Lilly and CompanyAbciximab

Myocardial Infarction With ST-Elevation

Start: Jan 2005Est. completion: Jan 2010292 patients
Phase 3Unknown
NCT00336830AstraZenecaMD-endorsed Cardiac Rehabilitation referral

Improving Cardiac Rehabilitation Participation in Women and Men

Start: May 2003Est. completion: Dec 20091,035 patients
Phase 3Completed
NCT00220571BiotronikCoronary Angioplasty

CARESS in Acute Myocardial Infarction

Start: May 2003Est. completion: Mar 2007600 patients
Phase 3Completed
NCT00681551BayerMagnevist

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis

Start: Feb 2003Est. completion: Mar 200445 patients
Phase 3Completed
NCT00245648Eli Lilly and Companyfibrinolytic therapy or combination reduced fibrinolytic therapy

Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI

Start: Jun 2001Est. completion: Oct 2007
Phase 3Completed
NCT00148460Boehringer IngelheimTNK-tPA

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

Start: Mar 2001Est. completion: Feb 2006270 patients
Phase 3Completed
NCT02181998Boehringer IngelheimFull dose tenecteplase

A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting

Start: Jul 20001,606 patients
Phase 3Completed
NCT02182011Boehringer IngelheimTenecteplase

A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Start: May 200049 patients
Phase 3Completed
NCT02181985Boehringer IngelheimFull dose TNK-tPA

Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

Start: May 20005,989 patients
Phase 3Completed
NCT00121446Rochetenecteplase

Which Therapy for Acute Heart Attacks? (The WEST Study)

Start: Jul 2003300 patients
Phase 2/3Completed
NCT06139328Boehringer IngelheimBI 765845

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Start: Dec 2023Est. completion: Dec 2025160 patients
Phase 2Terminated
NCT05327855Valo TherapeuticsOPL-0301 Dose 1

Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)

Start: Sep 2022Est. completion: Nov 2024
Phase 2Withdrawn
NCT04032925Miracor MedicalPICSO

The Pressure-controlled Intermittent Coronary Sinus Occlusion on VentrIcular PERformance Study

Start: Aug 2021Est. completion: Dec 2022
Phase 2Terminated
NCT03715998GenomicsRamipril

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Start: Jun 2019Est. completion: Jul 2021295 patients
Phase 2Completed
NCT01522417MedicureShort Tirofiban

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

Start: Apr 2012Est. completion: Mar 2019
Phase 2Completed
NCT02492243Rhythm PharmaceuticalsPCI

Continuous Rhythm Monitoring in Patients After Acute Myocardial infaRction andpREServed Lef venTricle Ejection Fraction (ARREST)

Start: Aug 2011Est. completion: Jun 2015
Phase 2Completed
NCT00966563Egetis TherapeuticsMangafodipir

Mangafodipir as an Adjunct to Percutaneous Coronary Intervention

Start: Dec 2009Est. completion: Jul 2013
Phase 2Completed
NCT00785954Bristol Myers SquibbKAI-9803

Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]

Start: Nov 2008Est. completion: May 20111,180 patients
Phase 2Completed
NCT00881075Eagle PharmaceuticalsSeeMore

Safety and Efficacy of SeeMore (TM) in Heart Patients

Start: Jun 2008Est. completion: Mar 2012
Phase 2Completed
NCT00310544BayerMagnevist

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

Start: Mar 2006Est. completion: Sep 200673 patients
Phase 2Completed
NCT01458405Capricor TherapeuticsCAP-1002 Allogeneic Cardiosphere-Derived Cells

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

Start: Nov 2012Est. completion: Feb 2019135 patients
Phase 1/2Terminated
NCT00883727Stempeutics ResearchStem cell

Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI

Start: Apr 2009Est. completion: Aug 2012
Phase 1/2Completed
NCT05629572Abbotti-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity

Abbott i-STAT High Sensitivity Troponin I Study

Start: Nov 2022Est. completion: Mar 20243,697 patients
N/ACompleted
NCT05098977T-TherapeuticsHeart rate variability measurement

The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction

Start: Nov 2021Est. completion: Oct 2024
N/AUnknown
NCT04139655Providence TherapeuticsColchicine 0.6 mg

Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study

Start: Sep 2020Est. completion: Oct 2021
N/AWithdrawn
NCT02594488Rhythm PharmaceuticalsMedtronic Reveal LINQ implantable cardiac monitor

Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction

Start: May 2016Est. completion: Feb 2021
N/ACompleted
NCT02341534BiotronikBioMonitor

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction

Start: Aug 2015Est. completion: Nov 2021802 patients
N/ACompleted
NCT03099395AstraZenecaPattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MI

Pattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MI

Start: Jun 2015Est. completion: Oct 2017100,000 patients
N/AUnknown
NCT02073942ZollCologne Register of Wearable Defibrillator (CRWD)

Cologne Register of Wearable Defibrillator (CRWD)

Start: Feb 2014Est. completion: Mar 2018
N/ACompleted
NCT01874262AstraZenecaMobile-phone based patient support

A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction

Start: Jun 2013Est. completion: Dec 2014174 patients
N/ACompleted
NCT01877941Nihon KohdenPulmonary Artery Catheter

Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time

Start: Dec 2012Est. completion: Dec 2013
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

15 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 150,093 patients
30 companies competing in this space